<?xml version="1.0" encoding="UTF-8"?>
<p>Nonalcoholic fatty liver disease (NAFLD), including fatty liver, liver fibrosis, and cirrhosis, have been known as common consequences of diabetes (Lankarani et al., 
 <xref rid="fsn32090-bib-0005" ref-type="ref">2013</xref>; Bellentani et al., 
 <xref rid="fsn32090-bib-0007" ref-type="ref">2010</xref>). Many rodent models of type 1 and type 2 diabetes have been established to explain the pathogenesis of diabetes and to test novel therapies for the suppression of complications of diabetes (King, 
 <xref rid="fsn32090-bib-0023" ref-type="ref">2012</xref>; Liang et al., 
 <xref rid="fsn32090-bib-0026" ref-type="ref">2015</xref>). Streptozotocin (STZ), a glucosamine‐nitrosourea compound, is used to induce diabetes in experimental animals (Noshahr et al., 
 <xref rid="fsn32090-bib-0036" ref-type="ref">2020</xref>; Rahman et al., 
 <xref rid="fsn32090-bib-0042" ref-type="ref">2018</xref>). STZ by the induction of oxidative stress and lipid peroxidation damages the pancreatic beta cells and impairs insulin production (Ghasemi et al., 
 <xref rid="fsn32090-bib-0016" ref-type="ref">2014</xref>).
</p>
